Aptatek BioSciences, Inc., is developing game-changing home monitoring tools for chronic disease patients and medication management. The Aptatek system combines its proprietary aptamer assay approach with a handheld, smartphone-based test platform. The company has already received Breakthrough Device designation by the FDA, for its first product - a phenylketonuria (PKU) monitoring test.
Aptatek’s proprietary design has been clinically proven with more than 40 small molecules that are otherwise not detectable outside the lab.
Unlike blood tests that are mailed to a central lab with results in weeks, Aptatek enables blood tests in real time allowing immediate adjustment of diet to ensure phenylalanine levels remain within clinical target ranges.
Aptatek is a handheld device that is battery powered and Bluetooth-enabled, allowing patients or doctors to use at home or as a point of care diagnostic device.
Aptatek’s core technology was developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall, faculty members at Columbia University Medical Center. The technology is based on DNA aptamer sequences that detect small molecule biomarkers which cannot be detected by antibodies. The sensitivity and specificity matches laboratory instruments including mass spectrometry.
Aptatek's proprietary aptamer design strategies and patented sequences create the opportunity for novel tests and new test strategies. The robust format is amenable to a variety of test platforms. The technology can be applied to monitor more than just PKU; Aptatek can detect a wide variety of markers that currently can only be measured in a lab.
CEO, President, Board of Directors
Sr. Technical Product Manager
Cofounder, Medical Advisor
Cofounder, Scientific Advisor
Chairman of the Board, Longview Innovation
Board Member, Canterbury Scientific LTD
Aptatek is looking to grow the team with passionate and hard working scientists, engineers, and business professionals. Pease submit your resume via the contact us form below.